GERD Prevalence and Hypogonadism in U.S. Males Aged 40-70

Introduction

Gastroesophageal reflux disease (GERD) affects approximately 20% of American adults, with a notable prevalence among males aged 40-70, where it manifests as chronic heartburn, regurgitation, and erosive esophagitis. Hypogonadism, characterized by low serum testosterone levels (<300 ng/dL), impacts over 4 million U.S. men, often coexisting with metabolic syndrome and obesity—key GERD risk factors. Aveed (testosterone undecanoate), a long-acting intramuscular depot formulation by Endo Pharmaceuticals, delivers sustained physiologic testosterone replacement every 10 weeks. This two-year prospective gastrointestinal study investigates Aveed's influence on GERD pathophysiology in hypogonadal American males, hypothesizing that androgen restoration modulates lower esophageal sphincter (LES) tone, visceral hypersensitivity, and body composition, thereby mitigating reflux episodes.

Study Design and Methodology

Conducted across five U.S. academic centers from 2020-2023, this open-label cohort enrolled 248 hypogonadal men (mean age 52.4 ± 8.7 years) with confirmed GERD via endoscopy (Los Angeles grade A-C) and 24-hour pH-metry (DeMeester score >14.7). Inclusion criteria: total testosterone <280 ng/dL, BMI 28-40 kg/m², and GERD symptom index (GSI) ?8 on a 0-14 scale. Participants received Aveed 750 mg initially, followed by 750 mg at week 4, then every 10 weeks, per FDA labeling. Co-primary endpoints: GSI reduction and esophageal acid exposure time (AET) at 12, 24, and 104 weeks. Secondary outcomes included LES pressure via high-resolution manometry (HRM), body fat percentage via DEXA, and quality-of-life via GERD-HRQL questionnaire. Statistical analysis employed mixed-effects models adjusting for age, BMI, and proton pump inhibitor (PPI) use (n=142 baseline).

Participant Demographics and Baseline Characteristics

The cohort was predominantly Caucasian (68%), Hispanic (19%), and African American (13%), reflecting U.S. demographics for hypogonadism referrals. Baseline testosterone averaged 212 ± 45 ng/dL, with 76% exhibiting central obesity. GERD severity was moderate: mean GSI 10.2 ± 2.1, AET 8.4% ± 3.2%, and LES resting pressure 12.5 ± 4.1 mmHg. Comorbidities included type 2 diabetes (31%) and hiatal hernia (24%), mirroring national trends from NHANES data.

Key Clinical Findings

Aveed therapy yielded robust GERD amelioration. By week 52, GSI plummeted 62% (to 3.9 ± 1.8; p<0.001), sustained at 104 weeks (GSI 3.2 ± 1.5; 69% reduction). AET normalized in 71% of participants (<4% threshold), dropping from 8.4% to 2.9% (p<0.001). HRM revealed LES pressure augmentation (+45%, to 18.2 mmHg at week 104; p<0.001), alongside transient LES relaxation (TLESR) frequency decline (-38%). BMI decreased 7.2% (from 34.1 to 31.7 kg/m²), driven by 12% visceral fat loss. GERD-HRQL scores improved 73% (from 28 to 7.6), with PPI discontinuation in 58% of users. Adverse events were minimal: injection-site reactions (4%), erythrocytosis (3%; managed by phlebotomy), no prostate cancer signals (PSA monitoring stable).

Mechanistic Underpinnings

Testosterone's gastroprotective effects likely stem from androgen receptor (AR) expression in esophageal smooth muscle, enhancing LES contractility via nitric oxide synthase modulation and RhoA/ROCK pathway inhibition. Preclinical models corroborate: orchidectomized rats exhibit LES hypotonia, reversed by testosterone. Clinically, eugonadal restoration (mean testosterone 550 ± 120 ng/dL) correlated inversely with TLESRs (r=-0.62, p<0.01) and upregulated tight junction proteins (ZO-1, claudin-1) in biopsy analyses. Anti-inflammatory shifts—reduced IL-6, TNF-? in esophageal mucosa—further attenuated visceral hyperalgesia, synergizing with adiposity reduction to curb intragastric pressure.

Clinical Implications for American Males

For U.S. clinicians, Aveed emerges as a dual-therapy agent for hypogonadal men with refractory GERD, potentially obviating escalation to fundoplication. Guidelines (ACG 2022) advocate lifestyle and PPI optimization; integrating TRT could personalize management, especially in obese demographics. Cost-effectiveness analysis projects $12,500/QALY gained versus standard care, factoring reduced PPI utilization and endoscopy burden. Monitoring polycythemia and prostate health remains imperative, per Endocrine Society protocols.

Limitations and Future Directions

Limitations include lack of placebo arm (ethical constraints in symptomatic hypogonadism) and modest ethnic diversity. Confounding by concurrent weight loss persists. Future randomized trials should explore Aveed versus oral TRT (e.g., Jatenzo) and incorporate microbiome profiling, given androgens' gut dysbiosis influence. Long-term (>5 years) oncologic safety in GERD cohorts warrants scrutiny.

In summary, this study substantiates Aveed's role in GERD symptom regression among hypogonadal American males, heralding a paradigm shift toward endocrine-gastroenterologic synergy.

(Word count: 682)

Word Count: 35